Tech Company Financing Transactions
CTRL Therapeutics Funding Round
CTRL Therapeutics, operating out of Chicago, secured $10 million from General Catalyst Partners, FACIT and Intermountain Healthcare.
Transaction Overview
Company Name
Announced On
4/10/2023
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
Proceeds Purpose
This funding enables further optimization and validation of our proprietary technology platform and expansion of our team to support our mission to deliver curative therapies for all individuals living with cancer
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 N Aberdeen St
Chicago, IL 60642
USA
Chicago, IL 60642
USA
Phone
Undisclosed
Website
Email Address
Overview
CTRL Therapeutics is developing a next-generation cell therapy platform with broad applicability across numerous solid tumors. The company's proprietary approach for the identification and isolation of circulating tumor-reactive lymphocytes (cTRLs) has the potential to unlock a new frontier in cell therapy for solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Juliana Thamrin
Chief Technical Officer
Shana Kelley
Co-Founder
Monica Evanti
Browse more venture capital transactions:
Prev: 4/10/2023: Fivecast venture capital transaction
Next: 4/10/2023: GiGstreem venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs